IDO1 and lung adenocarcinoma: Therefore, the current study was designed to assess the expression of IDO1 and biomarkers of T cell subsets (CD3, CD4, and CD8) in the lung adenocarcinomas as well as adjacent normal lung tissues, which were resected from the patients at stage I, II, and III lung adenocarcinoma.